Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
- 28 February 2002
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (1) , 87-92
- https://doi.org/10.1053/sonc.2002.30148
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Health Physics Consequences of Out-Patient Treatment of Non-Hodgkinʼs Lymphoma with 131I-radiolabeled Anti-B1 AntibodyHealth Physics, 2000
- Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood, 2000
- Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Clinical applications of anti-CD20 antibodiesJournal of Laboratory and Clinical Medicine, 1999
- Radioimmunotherapy for lymphomaCurrent Opinion in Oncology, 1999
- Update: A Revolution in the Treatment of Non-Hodgkin's LymphomaCancer Biotherapy & Radiopharmaceuticals, 1998
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996